Article Text

other Versions

Adalimumab improves joint- and skin-related functional impairment in patients with psoriatic arthritis: Patient- reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT)
  1. Dafna D Gladman (dafna.gladman{at}
  1. Centre for Prognosis Studies, Toronto Western Hospital, Canada
    1. Philip J Mease
    1. University of Washington School of Medicine, United States
      1. Mary A Cifaldi
      1. Global Health Economics & Outcomes Research, Abbott Laboratories, United States
        1. Renee J Perdok
        1. Clinical Statistics, Abbott Laboratories, United States
          1. Eric Sasso
          1. Abbott Immunology, Abbott Laboratories, United States
            1. John Medich
            1. Rheumatology, Immunoscience, Abbott Laboratories, United States


              Objective: To evaluate the effects of adalimumab on patient-reported outcomes of joint- and skin-related functional impairment, health-related quality of life (HRQOL), fatigue, and pain in patients with psoriatic arthritis (PsA).

              Methods: Patients with moderately to severely active PsA were treated with adalimumab 40 mg every other week or placebo in this 24-week, randomised, controlled trial. Patient-reported outcomes included the Health Assessment Questionnaire Disability Index (HAQ DI), Short Form 36 Health Survey (SF-36), the Functional Assessment of Chronic Illness Therapy-Fatigue scale (FACIT-Fatigue), and the Dermatology Life Quality Index (DLQI).

              Results: Adalimumab (N=151) and placebo (N=162) groups were comparable with respect to baseline demographics and disease severity. Statistically significant changes from baseline in HAQ DI were reported for adalimumab vs. placebo (-0.4 vs. & -0.1, p<0.001) at both Weeks 12 and 24. At Week 24, statistically significant improvements in the SF-36 domains of Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, and Social Functioning, as well as the Physical Component Summary score, were observed for adalimumab vs. placebo (p<0.01). These reported changes in HAQ DI and SF-36 were also clinically important. Significantly more adalimumab patients had complete resolution of functional loss (HAQ DI=0) and dermatologic-related functional limitations (DLQI=0) compared with placebo at Weeks 12 and 24 (p≤ 0.001). Adalimumab led to significantly greater improvements in FACIT-Fatigue scores, pain scores, and disease activity measures vs. placebo at Weeks 12 and 24 (p<0.001 for all).

              Conclusions: Adalimumab improved physical- and dermatologic-related functional limitations, HRQOL, fatigue, and pain in patients with PsA treated for 24 weeks.

              • adalimumab
              • patient-reported outcomes
              • psoriatic arthritis
              • quality of life
              • randomised controlled trial

              Statistics from

              Request permissions

              If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.